Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03787004 · ClinicalTrials.gov registry record · Phase 1
A Placebo-Controlled, Two-Part Study, Oral Dose to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CNTX-6970 in Healthy Subjects
A Phase 1 study, sponsored by Centrexion Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT03787004 is a Phase 1 study that has completed, run by Centrexion Therapeutics. The registered enrollment target is 62 participants.
The verdict
NCT03787004, a Phase 1 study, has completed, sponsored by Centrexion Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
A Phase 1, placebo-controlled, two part study with either single dose or multiple increasing oral dose to evaluate the safety, pharmacokinetics, and pharmacodynamics of CNTX-6970 in healthy subjects.
Interventions
- OTHER Placebo
- DRUG CNTX-6970
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2017-08-14 |
| Est. Completion | 2018-09-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03787004
The ClinicalTrials.gov registry entry for NCT03787004 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centrexion Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03787004 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03787004 about?
NCT03787004 is a clinical study titled "A Placebo-Controlled, Two-Part Study, Oral Dose to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CNTX-6970 in Healthy Subjects". A Phase 1, placebo-controlled, two part study with either single dose or multiple increasing oral dose to evaluate the safety, pharmacokinetics, and pharmacodynamics of CNTX-6970 in healthy subjects.
What is the current status of trial NCT03787004?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2017-08-14. Estimated completion is 2018-09-26.
What interventions are being tested in trial NCT03787004?
The interventions under investigation include: Placebo (OTHER), CNTX-6970 (DRUG).
Who is sponsoring clinical trial NCT03787004?
This trial is sponsored by Centrexion Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.